Nuvectis Pharma logo
Nuvectis Pharma
NVCT | NASDAQ
Chart Builder DCF Calculator
$19.11
-$1.13 (-5.58%)
At close: Nov 16, 2026, 4:00 PM ET
$19.11
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Nuvectis Pharma Company Profile

Company profile explained

Company Profile

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Key Executives

Name Position
Ron Bentsur Co-Founder, Chairman, Chief Executive Officer & President
Enrique Poradosu Co-Founder, Executive Vice President, Chief Scientific & Business Officer
Michael Carson Vice President of Finance
Shay Shemesh Co-Founder, Executive Vice President, Chief Development & Operations Officer

Latest SEC Filings

Date Type Title
Aug 28, 2026 EFFECT Filing
Aug 21, 2026 S-3 Filing
Aug 21, 2026 8-K Current Report
Aug 06, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Aug 05, 2026 4 Filing
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jul 01, 2026 4 Filing
Jul 01, 2026 4 Filing
Jun 30, 2026 8-K Current Report
View All SEC Filings ➞
Nuvectis Pharma
Nuvectis Pharma logo
Country United States
IPO Date Feb 4, 2022
Industry Biotechnology
Sector Healthcare
Employees 16
CEO Ron Bentsur

Contact Details

1 Bridge Plaza Fort Lee, New Jersey 07024 United States

Stock Details

Ticker Symbol NVCT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001875558
CUSIP Number 67080T108
ISIN Number US67080T1088
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.